Nantkwest (NK) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Nantkwest (NASDAQ:NK) from a buy rating to a hold rating in a research report released on Thursday, Zacks.com reports.

According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “

Shares of Nantkwest stock traded down $0.06 on Thursday, hitting $1.05. 4,042 shares of the company were exchanged, compared to its average volume of 317,484. The stock has a market cap of $110.51 million, a P/E ratio of -0.87 and a beta of 2.60. Nantkwest has a 1-year low of $0.93 and a 1-year high of $4.23. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.09 and a quick ratio of 4.09.

Several institutional investors have recently modified their holdings of NK. Creative Planning acquired a new position in shares of Nantkwest during the 1st quarter worth approximately $28,000. Edge Wealth Management LLC boosted its holdings in shares of Nantkwest by 100.0% during the 1st quarter. Edge Wealth Management LLC now owns 20,000 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 10,000 shares during the last quarter. Paloma Partners Management Co acquired a new position in shares of Nantkwest during the 4th quarter worth approximately $43,000. Rhumbline Advisers boosted its holdings in shares of Nantkwest by 33.4% during the 4th quarter. Rhumbline Advisers now owns 38,242 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 9,570 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Nantkwest during the 4th quarter worth approximately $49,000. Institutional investors and hedge funds own 8.52% of the company’s stock.

About Nantkwest

NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

See Also: Dividend Stocks – Are They Right For You?

Get a free copy of the Zacks research report on Nantkwest (NK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.